1,088 results on '"Schnittger, S"'
Search Results
252. Minimal residual disease diagnostics in myeloid malignancies in the post transplant period
253. Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype
254. Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice
255. 20p12.3 microdeletion predisposes to Wolff-Parkinson-White syndrome with variable neurocognitive deficits
256. NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia
257. NPM1-mutated acute myeloid leukaemia occurring in JAK2-V617F+ primary myelofibrosis: de-novo origin?
258. Real-Time Quantitative PCR (RQ-PCR) Detection of Minimal Residual Disease (MRD) by Optimized WT1 Assay To Enhance Risk Stratification in Acute Myeloid Leukemia (AML): A European LeukemiaNet Study.
259. A new case with rare e6a2 BCR–ABL fusion transcript developing two new resistance mutations during imatinib mesylate, which were replaced by T315I after subsequent dasatinib treatment
260. Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgVH status and immunophenotyping
261. Detection of an MPLW515 mutation in a case with features of both essential thrombocythemia and refractory anemia with ringed sideroblasts and thrombocytosis
262. Older-age AML: Disease biology and dose response
263. A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia
264. C009 Identification of dysplastic features in patients with myelodysplastic syndromes by multiparameter flow cytometry and correlation with cytomorphology and cytogenetics
265. JAK2V617F as progression marker in CMPD and as cooperative mutation in AML with trisomy 8 and t(8;21): a comparative study on 1103 CMPD and 269 AML cases
266. The quality of molecular response to chemotherapy is predictive for the outcome of AML1-ETO-positive AML and is independent of pretreatment risk factors
267. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma
268. Rare CBFB-MYH11 fusion transcripts in AML with inv(16)/t(16;16) are associated with therapy-related AML M4eo, atypical cytomorphology, atypical immunophenotype, atypical additional chromosomal rearrangements and low white blood cell count: a study on 162 patients
269. Magnetostatic interactions in patterned CoPt films embedded in a permalloy matrix
270. Use of five-color staining improves the sensitivity of multiparameter flow cytomeric assessment of minimal residual disease in patients with acute myeloid leukemia
271. Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event.
272. WT1 mutations are secondary events in AML, show varying frequencies and impact on prognosis between genetic subgroups.
273. Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status.
274. Gene expression profiling for the diagnosis of acute leukaemia
275. JAK2 seems to be a typical cooperating mutation in therapy-related t(8;21)/ AML1-ETO-positive AML
276. Identification of additional cytogenetic and molecular genetic abnormalities in acute myeloid leukaemia with t(8;21)/AML1-ETO
277. Report on two novel nucleotide exchanges in the JAK2 pseudokinase domain: D620E and E627E
278. The MLL recombinome of acute leukemias
279. Effect of systemic hormonal cyclicity on skin
280. Long Term Observation of CML Patients after Imatinib Resistance Associated with BCR-ABL Mutations.
281. Towards a pathogenesis-oriented therapy of acute myeloid leukemia
282. A rare case of acute myeloid leukemia with a CHIC2-ETV6 fusiongen and multiple other molecular aberrations
283. Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia
284. Genomic gains and losses influence expression levels of genes located within the affected regions: a study on acute myeloid leukemias with trisomy 8, 11, or 13, monosomy 7, or deletion 5q
285. New insights into MLL gene rearranged acute leukemias using gene expression profiling: shared pathways, lineage commitment, and partner genes
286. Mutations of the gene coding for the receptor tyrosin kinase FLT3 in acute myeloid leukemia
287. Reduced-intensity conditioning using TBI (8 Gy), fludarabine, cyclophosphamide and ATG in elderly CML patients provides excellent results especially when performed in the early course of the disease
288. The use of housekeeping genes for real-time PCR-based quantification of fusion gene transcripts in acute myeloid leukemia
289. Myelodysplastic syndrome (RARS) with +i(12p) abnormality in a patient 10�months after diagnosis and successful treatment of a mediastinal germ cell tumor (MGCT)
290. A PCR-based method allows the identification of any MLL translocation
291. Genexpressionsanalysen bei akuten Leukämien: Diagnostik der Zukunft? / Gene expression profiling in acute leukemia: diagnostics of the future?
292. Pediatric acute lymphoblastic leukemia (ALL) gene expression signatures classify an independent cohort of adult ALL patients
293. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML
294. Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate
295. Neue Methode zur Diagnostik von Leukämien: DNA-Microarrays
296. Karyotype instability between diagnosis and relapse in 117 patients with acute myeloid leukemia: implications for resistance against therapy
297. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases
298. A comprehensive leukemia database: integration of cytogenetics, molecular genetics and microarray data with clinical information, cytomorphology and immunophenotyping
299. Hsp70-peptide activated autologous NK cells in the immunotherpay of cancer — a clinical pilot study
300. Low CD62L- expression in acute myeloid leukemia (AML) correlates with a bad cytogenetic risk
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.